Torrent Pharmaceuticals Past Earnings Performance
Past criteria checks 6/6
Torrent Pharmaceuticals has been growing earnings at an average annual rate of 12.4%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 6.1% per year. Torrent Pharmaceuticals's return on equity is 22.3%, and it has net margins of 14.3%.
Key information
12.4%
Earnings growth rate
12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 6.1% |
| Return on equity | 22.3% |
| Net Margin | 14.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Torrent Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 104,742 | 14,942 | 19,662 | 0 |
| 30 Sep 23 | 102,332 | 13,432 | 18,932 | 0 |
| 30 Jun 23 | 98,642 | 12,692 | 17,842 | 0 |
| 31 Mar 23 | 96,202 | 12,452 | 17,052 | 0 |
| 31 Dec 22 | 92,580 | 8,312 | 16,233 | 0 |
| 30 Sep 22 | 88,750 | 7,972 | 15,883 | 0 |
| 30 Jun 22 | 87,210 | 8,012 | 15,833 | 0 |
| 31 Mar 22 | 85,080 | 7,772 | 15,483 | 0 |
| 31 Dec 21 | 83,158 | 12,189 | 15,227 | 0 |
| 30 Sep 21 | 82,028 | 12,669 | 14,977 | 0 |
| 30 Jun 21 | 80,828 | 12,609 | 14,717 | 0 |
| 31 Mar 21 | 80,046 | 12,519 | 14,597 | 0 |
| 31 Dec 20 | 80,143 | 12,417 | 14,350 | 0 |
| 30 Sep 20 | 79,853 | 11,957 | 14,260 | 0 |
| 30 Jun 20 | 79,733 | 11,297 | 14,210 | 0 |
| 31 Mar 20 | 79,393 | 10,247 | 14,421 | 0 |
| 31 Dec 19 | 78,488 | 5,593 | 14,398 | 0 |
| 30 Sep 19 | 79,338 | 5,543 | 14,538 | 0 |
| 30 Jun 19 | 78,228 | 4,893 | 14,388 | 0 |
| 31 Mar 19 | 76,728 | 4,363 | 14,038 | 0 |
| 31 Dec 18 | 75,141 | 8,161 | 13,743 | 0 |
| 30 Sep 18 | 69,891 | 6,281 | 12,783 | 0 |
| 30 Jun 18 | 65,121 | 6,531 | 12,183 | 0 |
| 31 Mar 18 | 59,498 | 6,781 | 11,353 | 0 |
| 31 Dec 17 | 56,727 | 6,556 | 10,674 | 0 |
| 30 Sep 17 | 56,387 | 8,266 | 10,284 | 0 |
| 30 Jun 17 | 56,387 | 8,296 | 10,044 | 0 |
| 31 Mar 17 | 58,157 | 9,336 | 9,934 | 0 |
| 31 Dec 16 | 59,154 | 10,014 | 10,233 | 0 |
| 30 Sep 16 | 60,144 | 10,624 | 9,913 | 0 |
| 30 Jun 16 | 62,744 | 13,644 | 9,393 | 0 |
| 31 Mar 16 | 66,669 | 17,332 | 8,424 | 0 |
| 31 Dec 15 | 63,315 | 16,299 | 18,653 | 0 |
| 30 Sep 15 | 59,605 | 13,139 | 18,583 | 0 |
| 30 Jun 15 | 54,865 | 9,439 | 18,723 | 0 |
| 31 Mar 15 | 46,535 | 7,509 | 8,772 | 0 |
| 31 Dec 14 | 47,247 | 8,649 | 16,510 | 0 |
| 30 Sep 14 | 45,717 | 8,559 | 16,310 | 0 |
| 30 Jun 14 | 43,267 | 7,709 | 15,890 | 0 |
| 31 Mar 14 | 41,847 | 6,639 | 15,770 | 0 |
| 31 Dec 13 | 38,291 | 5,308 | 13,901 | 0 |
| 30 Sep 13 | 36,111 | 4,858 | 13,631 | 0 |
| 30 Jun 13 | 33,781 | 4,798 | 13,361 | 0 |
Quality Earnings: 500420 has high quality earnings.
Growing Profit Margin: 500420's current net profit margins (14.3%) are higher than last year (9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500420's earnings have grown by 12.4% per year over the past 5 years.
Accelerating Growth: 500420's earnings growth over the past year (79.8%) exceeds its 5-year average (12.4% per year).
Earnings vs Industry: 500420 earnings growth over the past year (79.8%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 500420's Return on Equity (22.3%) is considered high.